Evox Therapeutics

Oxford, United Kingdom

Profile last updated: 2026-09-28

Hybrid — also manufactures internal programs

Exosome

2 partnership announcements in press monitoring · Last scored 2026-09-07

56.5

Signal Score

○ FDA Inspections ○ Clinical Trials ○ SEC Filings ✓ Press (2) ○ EMA GMP ○ MHRA GMP

Quick Facts: Evox Therapeutics

Signal Score: 56.5/100 (as of 2026-09-07)
Quality Compliance: Assessment pending
Headquarters: Oxford, United Kingdom
Modalities: Exosome
Active Programs: Data pending
Data Sources: FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By: CDMO Signal — independent CDMO intelligence platform

About Evox Therapeutics

Hybrid developer + CDMO.

Signal Score & Pillar Breakdown

Scores are being republished. Scores are being republished under methodology v3.3. The score shown is the last complete v3.2 result, which is also what directory listings and search results show. A pillar breakdown is not shown because the current one is computed under v3.3 and would not explain a v3.2 score. Regulatory evidence below is current.

Quality Compliance —

No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.

FDA InspectionsNo US records on file

Operations —

No ClinicalTrials.gov facility matches confirmed for this manufacturer. 2 partnership announcements found in press monitoring.

Programs — no verified data

Sponsors— no verified data

ModalitiesExosome

Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.

Partnership Announcements (from press monitoring)

Evox Therapeutics Partners with Rett Syndrome Research Trust to Evaluate ExoEdit® Technology to Enable Gene Editing in Rett Syndrome - BioSpace

2026-02-26